Researcher profile

Jitka Polechová

Jitka Polechová contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 13 - UnverifiedVerification L1Unclaimed author
2works
0followers
2topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

2 published item(s)

preprint2022arXiv

Robust models of SARS-CoV-2 heterogeneity and control

In light of the continuing emergence of new SARS-CoV-2 variants and vaccines, we create a simulation framework for exploring possible infection trajectories under various scenarios. The situations of primary interest involve the interaction between three components: vaccination campaigns, non-pharmaceutical interventions (NPIs), and the emergence of new SARS-CoV-2 variants. Additionally, immunity waning and vaccine boosters are modeled to account for their growing importance. New infections are generated according to a hierarchical model in which people have a random, individual infectiousness. The model thus includes super-spreading observed in the COVID-19 pandemic. Our simulation functions as a dynamic compartment model in which an individual's history of infection, vaccination, and possible reinfection all play a role in their resistance to further infections. We present a risk measure for each SARS-CoV-2 variant, $ρ^\V$, that accounts for the amount of resistance within a population and show how this risk changes as the vaccination rate increases. Furthermore, by considering different population compositions in terms of previous infection and type of vaccination, we can learn about variants which pose differential risk to different countries. Different control strategies are implemented which aim to both suppress COVID-19 outbreaks when they occur as well as relax restrictions when possible. We demonstrate that a controller that responds to the effective reproduction number in addition to case numbers is more efficient and effective in controlling new waves than monitoring case numbers alone. This is of interest as the majority of the public discussion and well-known statistics deal primarily with case numbers.

preprint2021arXiv

Evidence suggests that SARS-CoV-2 rapid antigen tests provide benefits for epidemic control -- observations from Austrian schools

Rapid antigen tests detect proteins at the surface of virus particles, identifying the disease during its infectious phase. In contrast, PCR tests detect viral genomes; they can thus diagnose COVID-19 before the infectious phase but also react to remnants of the virus genome, even weeks after live virus ceases to be detectable in the respiratory tract. Furthermore, the logistics for administering the tests are different, with rapid antigen tests being much easier to administer at-scale. In this article, we discuss the relative advantages of the different testing procedures and summarise evidence that shows that using antigen tests 2-3 times per week could become a powerful tool to suppress the COVID-19 pandemic. We also discuss the results of recent large-scale rapid antigen testing in Austrian schools. While our report on testing predates Delta, we have updated the review with recent data on viral loads in breakthrough infections and more information about testing efficacy, especially in children.